The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in alzheimer's disease

John J. Sramek; Neal R. Cutler1; Daniel J. Hurley; Randall D. Seifert1

doi:10.1016/0278-5846(94)00107-S

The utility of salivary amylase as an evaluation of M₃ muscarinic agonist activity in alzheimer's disease

John J. Sramek, Neal R. Cutler1, Daniel J. Hurley, Randall D. Seifert1

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

1. 1. In this double-blind, placebo-controlled phase I study of the safety/tolerance of two doses of xanomeline tartrate (100 mg and 115 mg tid) given to 12 AD patients, the authors measured serum amylase, fractionated into pancreatic and salivary isoenzymes, as a potential marker for M₃ activity associated with maximally tolerated dose (MTD). 2. 2. MTD of xanomeline was determined to be 100 mg tid based on intolerable adverse events at 115 mg tid. One patient at the 115 mg tid level presented with moderate hypersalivation and salivary amylase levels 400% of baseline. 3. 3. Overall amylase results were not significant, however a trend in the results for salivary amylase in the 115mg panel suggests that salivary amylase may be a useful marker for M₃ activity.

Original language	English (US)
Pages (from-to)	85-91
Number of pages	7
Journal	Progress in Neuropsychopharmacology and Biological Psychiatry
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/0278-5846(94)00107-S
State	Published - Jan 1995
Externally published	Yes

Keywords

Alzheimer's disease
LY246708
amylase
muscarinic receptors
xanomeline

Access

10.1016/0278-5846(94)00107-S

OpenUrl availability

Full text

Cite this

@article{752b173a2f534397a479fe812c416dc0,

title = "The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in alzheimer's disease",

abstract = "1. 1. In this double-blind, placebo-controlled phase I study of the safety/tolerance of two doses of xanomeline tartrate (100 mg and 115 mg tid) given to 12 AD patients, the authors measured serum amylase, fractionated into pancreatic and salivary isoenzymes, as a potential marker for M3 activity associated with maximally tolerated dose (MTD). 2. 2. MTD of xanomeline was determined to be 100 mg tid based on intolerable adverse events at 115 mg tid. One patient at the 115 mg tid level presented with moderate hypersalivation and salivary amylase levels 400% of baseline. 3. 3. Overall amylase results were not significant, however a trend in the results for salivary amylase in the 115mg panel suggests that salivary amylase may be a useful marker for M3 activity.",

keywords = "Alzheimer's disease, LY246708, amylase, muscarinic receptors, xanomeline",

author = "Sramek, {John J.} and Cutler1, {Neal R.} and Hurley, {Daniel J.} and Seifert1, {Randall D.}",

year = "1995",

month = jan,

doi = "10.1016/0278-5846(94)00107-S",

language = "English (US)",

volume = "19",

pages = "85--91",

journal = "Progress in Neuropsychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in alzheimer's disease

AU - Sramek, John J.

AU - Cutler1, Neal R.

AU - Hurley, Daniel J.

AU - Seifert1, Randall D.

PY - 1995/1

Y1 - 1995/1

N2 - 1. 1. In this double-blind, placebo-controlled phase I study of the safety/tolerance of two doses of xanomeline tartrate (100 mg and 115 mg tid) given to 12 AD patients, the authors measured serum amylase, fractionated into pancreatic and salivary isoenzymes, as a potential marker for M3 activity associated with maximally tolerated dose (MTD). 2. 2. MTD of xanomeline was determined to be 100 mg tid based on intolerable adverse events at 115 mg tid. One patient at the 115 mg tid level presented with moderate hypersalivation and salivary amylase levels 400% of baseline. 3. 3. Overall amylase results were not significant, however a trend in the results for salivary amylase in the 115mg panel suggests that salivary amylase may be a useful marker for M3 activity.

AB - 1. 1. In this double-blind, placebo-controlled phase I study of the safety/tolerance of two doses of xanomeline tartrate (100 mg and 115 mg tid) given to 12 AD patients, the authors measured serum amylase, fractionated into pancreatic and salivary isoenzymes, as a potential marker for M3 activity associated with maximally tolerated dose (MTD). 2. 2. MTD of xanomeline was determined to be 100 mg tid based on intolerable adverse events at 115 mg tid. One patient at the 115 mg tid level presented with moderate hypersalivation and salivary amylase levels 400% of baseline. 3. 3. Overall amylase results were not significant, however a trend in the results for salivary amylase in the 115mg panel suggests that salivary amylase may be a useful marker for M3 activity.

KW - Alzheimer's disease

KW - LY246708

KW - amylase

KW - muscarinic receptors

KW - xanomeline

UR - http://www.scopus.com/inward/record.url?scp=0028795476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028795476&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(94)00107-S

DO - 10.1016/0278-5846(94)00107-S

M3 - Article

C2 - 7535938

AN - SCOPUS:0028795476

SN - 0278-5846

VL - 19

SP - 85

EP - 91

JO - Progress in Neuropsychopharmacology and Biological Psychiatry

JF - Progress in Neuropsychopharmacology and Biological Psychiatry

IS - 1

ER -